Viridian Therapeutics: Promising Future with Strategic Trials and Financial Stability
Viridian Therapeutics is viewed positively by analyst Serge Belanger, who has issued a Buy rating due to the company's promising future. The completion of enrollment for Phase 3 REVEAL trials for drug VRDN-003 is a significant milestone, with results expected in 2026. The company has also filed a Biologics License Application for its drug veli, with FDA acceptance anticipated soon. Financially, Viridian has secured up to $889 million, enhancing its stability for future developments. Wedbush also maintains a Buy rating with a $42 price target.
Serge Belanger has given his Buy rating due to a combination of factors that highlight Viridian Therapeutics’ promising future. The company has recently completed the enrollment for its Phase 3 REVEAL trials, which are critical for evaluating the subcutaneous version of their drug, VRDN-003. The anticipated results from these trials are expected in the first and second quarters of 2026, setting the stage for a Biologics License Application (BLA) filing by the end of 2026.
Additionally, Viridian Therapeutics has successfully filed a BLA for their drug veli, with the FDA’s acceptance anticipated by late December or early January. This could potentially lead to a Priority Review and a possible approval by mid-2026. Furthermore, the company has bolstered its financial position through recent financing transactions, securing up to $889 million, which, combined with their existing cash reserves, positions them well for future developments. These strategic moves and financial stability underpin Belanger’s optimistic outlook and Buy rating for Viridian Therapeutics.
According to TipRanks, Belanger is a 4-star analyst with an average return of 8.4% and a 47.60% success rate. Belanger covers the Healthcare sector, focusing on stocks such as Viridian Therapeutics, Cormedix, and Amphastar Pharmaceuticals.
In another report released today, Wedbush also maintained a Buy rating on the stock with a $42.00 price target.
